These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

188 related articles for article (PubMed ID: 25841321)

  • 1. Atomoxetine reverses locomotor hyperactivity, impaired novel object recognition, and prepulse inhibition impairment in mice lacking pituitary adenylate cyclase-activating polypeptide.
    Shibasaki Y; Hayata-Takano A; Hazama K; Nakazawa T; Shintani N; Kasai A; Nagayasu K; Hashimoto R; Tanida M; Katayama T; Matsuzaki S; Yamada K; Taniike M; Onaka Y; Ago Y; Waschek JA; Köves K; Reglődi D; Tamas A; Matsuda T; Baba A; Hashimoto H
    Neuroscience; 2015 Jun; 297():95-104. PubMed ID: 25841321
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pituitary adenylate cyclase-activating polypeptide deficient mice show length abnormalities of the axon initial segment.
    Iwahashi M; Yoshimura T; Harigai W; Takuma K; Hashimoto H; Katayama T; Hayata-Takano A
    J Pharmacol Sci; 2023 Nov; 153(3):175-182. PubMed ID: 37770159
    [TBL] [Abstract][Full Text] [Related]  

  • 3. An enriched environment ameliorates memory impairments in PACAP-deficient mice.
    Takuma K; Maeda Y; Ago Y; Ishihama T; Takemoto K; Nakagawa A; Shintani N; Hashimoto H; Baba A; Matsuda T
    Behav Brain Res; 2014 Oct; 272():269-78. PubMed ID: 25014004
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The Atxn7-overexpressing mice showed hyperactivity and impulsivity which were ameliorated by atomoxetine treatment: A possible animal model of the hyperactive-impulsive phenotype of ADHD.
    Dela Peña IJI; Botanas CJ; de la Peña JB; Custodio RJ; Dela Peña I; Ryoo ZY; Kim BN; Ryu JH; Kim HJ; Cheong JH
    Prog Neuropsychopharmacol Biol Psychiatry; 2019 Jan; 88():311-319. PubMed ID: 30125623
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The selective metabotropic glutamate 2/3 receptor agonist MGS0028 reverses psychomotor abnormalities and recognition memory deficits in mice lacking the pituitary adenylate cyclase-activating polypeptide.
    Ago Y; Hiramatsu N; Ishihama T; Hazama K; Hayata-Takano A; Shibasaki Y; Shintani N; Hashimoto H; Kawasaki T; Onoe H; Chaki S; Nakazato A; Baba A; Takuma K; Matsuda T
    Behav Pharmacol; 2013 Feb; 24(1):74-7. PubMed ID: 23268987
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Methamphetamine-induced hyperactivity and behavioral sensitization in PACAP deficient mice.
    Fujii H; Ishihama T; Ago Y; Shintani N; Kakuda M; Hashimoto H; Baba A; Matsuda T
    Peptides; 2007 Sep; 28(9):1674-9. PubMed ID: 17658665
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Altered behavioral response to centrally acting drugs in mice lacking PACAP].
    Shintani N; Tanaka K; Hashimoto H; Baba A
    Nihon Yakurigaku Zasshi; 2003 Nov; 122 Suppl():1P-4P. PubMed ID: 14727506
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pituitary adenylate cyclase-activating polypeptide is associated with schizophrenia.
    Hashimoto R; Hashimoto H; Shintani N; Chiba S; Hattori S; Okada T; Nakajima M; Tanaka K; Kawagishi N; Nemoto K; Mori T; Ohnishi T; Noguchi H; Hori H; Suzuki T; Iwata N; Ozaki N; Nakabayashi T; Saitoh O; Kosuga A; Tatsumi M; Kamijima K; Weinberger DR; Kunugi H; Baba A
    Mol Psychiatry; 2007 Nov; 12(11):1026-32. PubMed ID: 17387318
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Atomoxetine Reestablishes Long Term Potentiation in a Mouse Model of Attention Deficit/Hyperactivity Disorder.
    Piña R; Rozas C; Contreras D; Hardy P; Ugarte G; Zeise ML; Rojas P; Morales B
    Neuroscience; 2020 Jul; 439():268-274. PubMed ID: 31809728
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Environmental factors during early developmental period influence psychobehavioral abnormalities in adult PACAP-deficient mice.
    Ishihama T; Ago Y; Shintani N; Hashimoto H; Baba A; Takuma K; Matsuda T
    Behav Brain Res; 2010 Jun; 209(2):274-80. PubMed ID: 20144662
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Atomoxetine treatment in adults with attention-deficit/hyperactivity disorder.
    Walker DJ; Mason O; Clemow DB; Day KA
    Postgrad Med; 2015; 127(7):686-701. PubMed ID: 26343377
    [TBL] [Abstract][Full Text] [Related]  

  • 12. An antihyperkinetic action by the serotonin 1A-receptor agonist osemozotan co-administered with psychostimulants or the non-stimulant atomoxetine in mice.
    Tsuchida R; Kubo M; Kuroda M; Shibasaki Y; Shintani N; Abe M; Köves K; Hashimoto H; Baba A
    J Pharmacol Sci; 2009 Mar; 109(3):396-402. PubMed ID: 19270432
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pituitary adenylate cyclase-activating polypeptide counteracts the impaired adult neural stem cell viability induced by palmitate.
    Mansouri S; Ortsäter H; Pintor Gallego O; Darsalia V; Sjöholm A; Patrone C
    J Neurosci Res; 2012 Apr; 90(4):759-68. PubMed ID: 22183970
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Atomoxetine blocks motor hyperactivity in neonatal 6-hydroxydopamine-lesioned rats: implications for treatment of attention-deficit hyperactivity disorder.
    Moran-Gates T; Zhang K; Baldessarini RJ; Tarazi FI
    Int J Neuropsychopharmacol; 2005 Sep; 8(3):439-44. PubMed ID: 15817135
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effects of acute and chronic administration of atomoxetine and methylphenidate on extracellular levels of noradrenaline, dopamine and serotonin in the prefrontal cortex and striatum of mice.
    Koda K; Ago Y; Cong Y; Kita Y; Takuma K; Matsuda T
    J Neurochem; 2010 Jul; 114(1):259-70. PubMed ID: 20403082
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Increased prefrontal hemodynamic change after atomoxetine administration in pediatric attention-deficit/hyperactivity disorder as measured by near-infrared spectroscopy.
    Ota T; Iida J; Nakanishi Y; Sawada S; Matsuura H; Yamamuro K; Ueda S; Uratani M; Kishimoto N; Negoro H; Kishimoto T
    Psychiatry Clin Neurosci; 2015 Mar; 69(3):161-70. PubMed ID: 25359429
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pituitary adenylate cyclase-activating polypeptide (PACAP) is important for embryo implantation in mice.
    Isaac ER; Sherwood NM
    Mol Cell Endocrinol; 2008 Jan; 280(1-2):13-9. PubMed ID: 17945412
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Melanotan II, a melanocortin agonist, partially rescues the impaired thermogenic capacity of pituitary adenylate cyclase-activating polypeptide deficient mice.
    McMillan TR; Forster MAM; Short LI; Rudecki AP; Cline DL; Gray SL
    Exp Physiol; 2021 Feb; 106(2):427-437. PubMed ID: 33332767
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The effects of atomoxetine and methylphenidate on the prepulse inhibition of the acoustic startle response in mice.
    Woo H; Park SJ; Lee Y; Kwon G; Gao Q; Lee HE; Ahn YJ; Shin CY; Cheong JH; Ryu JH
    Prog Neuropsychopharmacol Biol Psychiatry; 2014 Oct; 54():206-15. PubMed ID: 24953433
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical Impact of Not Achieving Recommended Dose on Duration of Atomoxetine Treatment in Adults with Attention-Deficit/Hyperactivity Disorder.
    Clemow DB; Nyhuis AW; Robinson RL
    CNS Neurosci Ther; 2016 Dec; 22(12):970-978. PubMed ID: 27476490
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.